West Pharmaceutical Services (NYSE: WST) stock fell by 1.87% despite a positive earnings report and upgraded earnings estimates, likely due to market reaction to overall economic conditions or investor sentiment despite better-than-expected results.

West Pharmaceutical Services (NYSE: WST) stock fell by 1

West Pharmaceutical Services (WST) shares experienced a 1.87% decline, despite a consensus rating of "Moderate Buy" from analysts and a record of positive quarterly earnings, likely due to market fluctuations or profit-taking following the stock's previous performance.

West Pharmaceutical Services (WST) shares experienced a 1

West Pharmaceutical Services (WST) stock fell by 2.18% despite raising its price target by UBS Group due to mixed investor sentiment, as multiple analysts offered varied ratings and expectations, with some potential concerns reflected in the stock's performance despite strong earnings results.

West Pharmaceutical Services (WST) stock fell by 2

West Pharmaceutical Services (WST) stock fell 5.59% after HighPoint Advisor Group LLC disclosed a 20.3% reduction in its stake in the company, amidst overall mixed institutional investment activity.

West Pharmaceutical Services (WST) stock fell 5

West Pharmaceutical Services (WST) stock decreased by 5.59% due to increasing bearish sentiment and short selling in the healthcare sector, as well as ongoing leadership transitions within the company.

West Pharmaceutical Services (WST) stock decreased by 5

West Pharmaceutical Services (NYSE: WST) experienced a 5.59% decline in stock value following its latest quarterly earnings report, which beat analyst expectations, perhaps due to profit-taking after the earnings surge and market corrections.

West Pharmaceutical Services (NYSE: WST) experienced a 5

West Pharmaceutical Services (WST) stock surged by 22.78% following a strong second-quarter earnings report that exceeded expectations and a raised full-year guidance, primarily driven by robust demand for its High-Value Product (HVP) segment and growth in GLP-1 elastomer products.

West Pharmaceutical Services (WST) stock surged by 22

West Pharmaceutical Services (WST) stock soared 22.78% following a strong second-quarter 2025 earnings and revenue report that exceeded expectations, coupled with a significant increase in its full-year guidance.

West Pharmaceutical Services (WST) stock soared 22

West Pharmaceutical Services (WST) stock surged by 22.78% due to positive market sentiment and potential strong earnings, driven by increased demand in the pharmaceutical sector amidst ongoing healthcare developments.

West Pharmaceutical Services (WST) stock surged by 22.78% following increased investments from institutional investors, strong quarterly earnings that exceeded estimates, and positive analyst ratings, including a "strong-buy" recommendation.

West Pharmaceutical Services (NYSE:WST) stock rose 4.2% as the company prepares to announce its Q2 2025 earnings, which are expected to exceed analysts' expectations, along with recent favorable analyst ratings and positive institutional investment trends.

West Pharmaceutical Services (NYSE:WST) stock rose 4

West Pharmaceutical Services' stock (WST) rose 4.2% following coverage initiation by Barclays analyst Luke Sergott, who assigned an Equal Weight rating and a price target of $245, despite highlighting challenges in its smaller segments and potential disruption from oral GLP-1 treatments, while emphasizing the company's strong position in its High-Value Products segment which drives significant revenue and profit.

West Pharmaceutical Services' stock (WST) rose 4

West Pharmaceutical Services (WST) stock declined by 0.38% as institutional investors adjusted their positions, reflecting ongoing market volatility and mixed performance indicators from recent earnings.

West Pharmaceutical Services (WST) stock declined by 0

West Pharmaceutical Services (WST) stock increased by 1.51% likely due to significant institutional buying, including a 49.4% increase in holdings by Ballentine Partners LLC and overall positive adjustments from other hedge funds, indicating strong investor confidence.

West Pharmaceutical Services (WST) stock increased by 1

West Pharmaceutical Services, Inc. (WST) stock experienced a decline of 1.53% due to recent revenue softness related to COVID-related inventory destocking, despite a promising long-term investment outlook amid favorable trends in the biopharmaceutical sector.

West Pharmaceutical Services, Inc

The article discusses a Q2 2025 investor letter from Brasada Capital Management that indicates West Pharmaceutical Services (WST) was purchased as an undervalued stock despite its recent decline of -1.18%. The decline in WST's stock could be attributed to general market volatility and short-term investor fears affecting many asset classes.

The article discusses a Q2 2025 investor letter from Brasada Capital Management that indicates West 

West Pharmaceutical Services (WST) stock declined by 1.18% due to broader market weaknesses, including weak corporate results and selling pressure in the IT sector, as well as concerns over global trade conditions and foreign fund outflows.

West Pharmaceutical Services (WST) stock declined by 1

West Pharmaceutical Services (WST) saw a decline of 0.89% in its stock price, attributed primarily to reported changes in institutional investment holdings, including a slight reduction by Principal Financial Group and recent fluctuations in overall investor sentiment despite the company's solid earnings report and growth in revenue.

West Pharmaceutical Services (WST) saw a decline of 0

West Pharmaceutical Services (WST) stock rose by 1.35% due to significant institutional investment activity, including a dramatic 1,459.5% increase in holdings by the Teacher Retirement System of Texas, as well as positive earnings results that surpassed expectations, prompting analysts to upgrade their ratings on the stock.

West Pharmaceutical Services (WST) stock rose by 1

West Pharmaceutical Services (WST) stock rose by 2.59% despite ongoing legal challenges and allegations of mismanagement, reflecting investor optimism perhaps due to a broader market trend or potential resolution of the investigations against the company.

West Pharmaceutical Services (WST) stock rose by 2

West Pharmaceutical Services (WST) stock increased by 0.47% due to heightened institutional investment, including a 43.7% stake increase by Bessemer Group and significant acquisitions by other hedge funds, reflecting growing confidence in the company's performance and future prospects.

West Pharmaceutical Services (WST) stock increased by 0

West Pharmaceutical Services (WST) stock recently declined by 0.54% amid ongoing legal scrutiny and allegations of misleading statements regarding their business performance and product margins, particularly following a significant drop in stock value due to disappointing revenue forecasts and operational inefficiencies.

West Pharmaceutical Services (WST) stock recently declined by 0

West Pharmaceutical Services (WST) stock declined by 0.54% due to the announcement of a class action lawsuit alleging that the company made false and misleading statements regarding its financial condition and product performance during a specified period, leading to investor losses when the truth was revealed.

West Pharmaceutical Services (WST) stock rose 1.65% last night amidst ongoing class action lawsuits regarding misleading corporate statements and financial discrepancies, as investors anticipate responses to these legal challenges.

West Pharmaceutical Services (WST) stock rose 1

West Pharmaceutical Services (WST) stock was up 1.65% following the announcement of a class action lawsuit alleging securities fraud against the company, which may have led to investor speculation or confidence in a potential favorable resolution.

West Pharmaceutical Services (WST) stock was up 1

West Pharmaceutical Services (WST) stock experienced a slight decline of 0.03% following a significant drop of 38.2% earlier this year due to disappointing revenue and earnings forecasts, compounded by operational challenges in its Contract Manufacturing segment and issues with its SmartDose wearable injector devices.

West Pharmaceutical Services (WST) stock experienced a slight decline of 0

West Pharmaceutical Services (WST) stock declined by 0.06% amid mixed institutional investor activity and general market conditions following a recent earnings report that showed a slight year-over-year revenue increase. The decline may be attributed to market volatility or investor reactions to changing analyst ratings rather than significant negative news specifically about the company.

West Pharmaceutical Services (WST) stock fell by 0.91% as a result of a class action lawsuit alleging that the company made false and misleading statements about its business operations, specifically regarding declines in product demand and profit margins related to its high-value product portfolio.

West Pharmaceutical Services (WST) stock fell by 0

West Pharmaceutical Services (WST) stock fell by 0.91% due to allegations of misleading statements and financial mismanagement, including ongoing product destocking and operational inefficiencies that impacted profit margins, leading to potential costly restructuring activities.

West Pharmaceutical Services (WST) stock fell by 0.75% following Barclays issuing an equal weight rating with a price target of $245.00, indicating a cautious outlook on the stock amid mixed analyst ratings and recent performance.

The article discusses the recent decline of West Pharmaceutical Services (WST) stock, which was down by 0.75%, due to market concerns influenced by the broader pressures faced in the medical technology sector, particularly relating to demand fluctuations and operational efficiency issues highlighted by activist investors in companies like Becton, Dickinson and Company.

The article discusses the recent decline of West Pharmaceutical Services (WST) stock, which was down

West Pharmaceutical Services (WST) stock declined by 0.75% amidst recent activity where institutional investors adjusted their positions, with significant buying and holding, despite a solid earnings report that surpassed analysts' expectations. The stock's drop could be attributed to broader market trends or profit-taking after previous gains, as it has been fluctuating between its one-year low and high.

West Pharmaceutical Services (WST) stock rose 2.76% amid ongoing class action lawsuits following a significant drop in its stock price earlier this year due to disappointing revenue and earnings forecasts, which have now prompted investor interest in potentially recovering losses. 

The uptick in WST's stock price could be attributed to renewed investor interest as the market reacts to the upcoming class action lawsuit and the potential for future reforms or improvements following past challenges.

West Pharmaceutical Services (WST) stock rose 2

West Pharmaceutical Services (WST) stock rose 2.76% as institutional investors, including the State of Alaska Department of Revenue, increased their stakes in the company, signaling confidence in its financial performance and growth potential.

West Pharmaceutical Services (WST) stock rose by 2.76% amid ongoing class action lawsuits against the company, likely due to investor speculation or confidence in the potential outcomes of these legal cases affecting the stock's performance positively.

West Pharmaceutical Services (WST) stock rose by 2.76% amid ongoing investigations into potential fraud claims involving the company, following significant losses reported earlier this year when the company's forecasts were issued. The increase in stock price could be attributed to investors reacting positively to potential resolutions of legal issues or market speculation.

West Pharmaceutical Services (WST) stock rose by 2.76% due to positive institutional investment activity, analyst upgrades to "buy" or "strong buy" ratings, and a strong quarterly earnings report that exceeded expectations.

West Pharmaceutical Services (WST) stock rose 0.41% as investors may be reacting positively to news of a class action lawsuit filed against the company due to alleged misleading statements impacting their financial performance, prompting those who purchased shares during a specified period to seek potential compensation.

West Pharmaceutical Services (WST) stock rose 0

West Pharmaceutical Services (WST) stock saw a 0.41% increase despite the announcement of a class action lawsuit related to securities fraud, which may indicate investor confidence in the company or a reaction to market dynamics.

West Pharmaceutical Services (WST) stock saw a 0

West Pharmaceutical Services (WST) stock declined by 0.98% following the announcement of a class action lawsuit alleging the company made false statements regarding its product demand and profit margins, which likely affected investor confidence.

West Pharmaceutical Services (WST) stock decreased by 0.05% due to a 7.3% reduction in holdings by Mn Services Vermogensbeheer B.V. during the first quarter, indicating potential investor concerns or adjustments in institutional investment strategies.

West Pharmaceutical Services (WST) stock decreased by 0

West Pharmaceutical Services (WST) stock experienced a -0.05% decline, which is attributed to ongoing concerns and legal claims regarding potential misleading statements from the company about its financial health and operational efficiencies, especially following a significant drop in stock price after revealing weak revenue projections.

West Pharmaceutical Services (WST) stock experienced a -0

West Pharmaceutical Services (WST) stock dropped by 2.78% as Elevation Point Wealth Partners LLC and other institutional investors reduced their positions in the company, indicating potential concerns regarding the stock's performance or market sentiment.

West Pharmaceutical Services (WST) stock dropped by 2

West Pharmaceutical Services (NYSE: WST) stock fell 2.78% due to ongoing concerns stemming from a class action lawsuit that alleges the company misrepresented its financial health and customer demand, particularly relating to margin pressures from its SmartDose device and losses from key contracts.

West Pharmaceutical Services (NYSE: WST) stock fell 2

West Pharmaceutical Services (WST) stock increased by 1.08% last night amid ongoing legal proceedings regarding a class action lawsuit related to the company's earlier disappointing financial performance, hinting that some investors may be finding opportunity in the stock despite previous setbacks.

West Pharmaceutical Services (WST) stock experienced a 0.4% increase amidst ongoing investigations and a class action lawsuit alleging the company misled investors about its business prospects, particularly related to margin pressures and operational issues with its SmartDose device. 

The stock's rise may be attributed to market reactions that often occur in the context of lawsuits, where investors speculate on potential settlements or resolutions that could positively impact the company's future.

West Pharmaceutical Services (WST) stock experienced a 0

West Pharmaceutical Services (WST) stock experienced a 0.4% increase amid ongoing legal scrutiny and a class action lawsuit related to significant misstatements about the company’s financial health and operational issues. 

The stock rise may be attributed to investor sentiment stabilizing after previous declines following the revelations of substantial operational challenges and poor earnings forecasts, leading some to perceive a potential buying opportunity or recover from prior losses.

West Pharmaceutical Services (WST) stock declined by 1.62% due to concern over a class action lawsuit alleging that the company made misleading statements about its financial health, specifically regarding ongoing destocking in its high-margin products and issues with operational efficiencies impacting profit margins.

West Pharmaceutical Services (WST) stock rose by 1.76% following a positive earnings report that exceeded analyst expectations, coupled with strong institutional investor interest, as demonstrated by increased stakes from several funds.

West Pharmaceutical Services (WST) stock rose by 1.76% as the company faces a class action lawsuit involving allegations of misleading statements regarding financial performance and margin pressures, which may have led to heightened investor interest and a short-term rebound amidst ongoing scrutiny.

West Pharmaceutical Services (WST) stock declined by 0.41% due to shareholders being alerted about a class action lawsuit alleging that the company made false statements and failed to disclose significant issues affecting its profit margins and customer demand during a specified class period.

West Pharmaceutical Services' stock (WST) fell by 0.41% as investors reacted negatively to a class action lawsuit stemming from the company's disappointing revenue and earnings forecasts, which were impacted by the loss of significant customers and the dilutive effect of its SmartDose devices on profit margins.

West Pharmaceutical Services' stock (WST) fell by 0

West Pharmaceutical Services (WST) stock is down by 0.41% due to the initiation of class action lawsuits against the company, which has raised concerns among investors.

West Pharmaceutical Services (WST) stock is down by 0

West Pharmaceutical Services (WST) stock increased by 2.8% amidst a class action lawsuit alleging securities fraud against the company, following its previously issued weak revenue and earnings forecasts. The rise in stock price may be attributed to investor speculation or market reactions to the ongoing litigation and potential outcomes, despite the company's recent challenges and losses in key customer contracts.

West Pharmaceutical Services (WST) stock increased by 2

West Pharmaceutical Services (NYSE:WST) stocks rose 2.8% following a series of positive analyst ratings, including a "strong-buy" upgrade from Stephens, and the company's recent strong quarterly earnings report, which exceeded expectations.

West Pharmaceutical Services (NYSE:WST) stocks rose 2

The article discusses a class action lawsuit against West Pharmaceutical Services, which has led to a 3.38% increase in their stock, likely due to investors speculating that the potential settlement could positively impact the company's future financial outlook.

The article discusses a class action lawsuit against West Pharmaceutical Services, which has led to 

West Pharmaceutical Services (WST) stock rose by 0.38% last night amidst significant institutional trading activity, including a mix of selling and buying by various funds, as well as favorable analyst upgrades indicating strong future performance. The stock's rise is likely due to positive quarterly earnings that exceeded expectations and multiple buy ratings from analysts, signaling confidence in the company's growth.

West Pharmaceutical Services (WST) stock rose by 0

West Pharmaceutical Services, Inc. (WST) saw a 0.38% increase in stock price, potentially due to market reactions to ongoing legal proceedings associated with allegations of misleading statements by the company regarding its financial health and product performance.

West Pharmaceutical Services (WST) stock saw a 0.6% increase likely due to recent market dynamics, despite ongoing legal challenges posed by class action lawsuits that accuse the company of making misleading statements regarding its business performance and future guidance.

West Pharmaceutical Services (WST) stock dropped by 0.69% amidst the announcement of a class action lawsuit related to alleged securities fraud and the company's previously issued weak revenue and earnings forecasts, primarily affected by challenges in its Contract Manufacturing segment.

West Pharmaceutical Services (WST) stock dropped by 0

West Pharmaceutical Services (WST) stock recently declined by 0.69% amid ongoing investor concerns following disappointing revenue and earnings forecasts attributed to contract manufacturing challenges and the dilutive effect of its SmartDose wearable injector devices.

West Pharmaceutical Services (WST) stock declined by 0.69% following allegations of securities law violations, including misleading statements about its financial performance and operational inefficiencies, particularly related to its SmartDose device and the loss of key contracts, which were revealed in a poor revenue and earnings forecast.

West Pharmaceutical Services, Inc. (WST) stock declined by 0.69% due to revelations from a securities fraud class action complaint that the company had misled investors about its customer demand visibility, ongoing product destocking, and issues with its SmartDose device that negatively impacted profit margins and led to weak revenue and earnings forecasts.

West Pharmaceutical Services (WST) stock rose 0.19% last night amid an investigation into potential fiduciary breaches by certain officers and directors related to undisclosed operational inefficiencies and market challenges.

West Pharmaceutical Services (WST) stock experienced a decline of -0.44% due to the announcement of a class action lawsuit alleging the company made misleading statements about its financial health and operations, specifically regarding issues with its high-margin products and profit margins.

West Pharmaceutical Services (WST) stock experienced a decline of -0

West Pharmaceutical Services (WST) stock fell by 0.44% following allegations that the company misled investors about customer demand, profit margins, and ongoing operational issues, which could potentially lead to costly restructuring efforts.

West Pharmaceutical Services (WST) stock fell by 0.44% due to a significant 82.9% reduction in holdings by Two Sigma Advisers LP, alongside mixed institutional investment activities and fluctuating analyst ratings that have created uncertainty about the stock's future performance.

West Pharmaceutical Services (WST) stock experienced a slight increase of 0.18%, despite ongoing legal investigations into potential securities fraud concerning misleading statements about the company’s financial health and operational issues. The stock may have gone up due to market corrections or investor speculation following significant declines following earlier negative disclosures about the company's performance.

West Pharmaceutical Services (WST) stock experienced a slight increase of 0

West Pharmaceutical Services (WST) stock rose by 2.64% amidst a backdrop of disappointing earnings forecasts and a class action lawsuit filed against the company for allegedly misleading investors about its business performance and prospects, suggesting that investors may be optimistic about the potential for recovery or resolution.

West Pharmaceutical Services (WST) stock declined by 1.39% due to ongoing legal challenges stemming from allegations of misleading business practices and undisclosed financial struggles, particularly related to inventory destocking and profit margin pressures.

West Pharmaceutical Services (WST) stock experienced a decline of -0.22% due to ongoing concerns highlighted in a class action lawsuit, which alleges that the company made misleading statements about customer demand and product performance, leading to disappointing revenue forecasts and margin pressures.

West Pharmaceutical Services (WST) stock fell by 3.01% due to allegations of misleading statements regarding its financial health and operational inefficiencies during a class action period, which highlighted issues such as significant destocking and margin pressures on its products.

West Pharmaceutical Services (WST) stock fell by 3

West Pharmaceutical Services (WST) stock fell by 0.82% following the announcement of a class action lawsuit alleging that the company made false statements about its business performance and experienced significant operational issues, which misled investors about its profitability and growth prospects.

West Pharmaceutical Services (WST) stock declined by 0.82% amidst a class action lawsuit alleging that the company and its executives misled investors about significant ongoing destocking and operational inefficiencies, alongside disappointing revenue forecasts that fell below expectations.

West Pharmaceutical Services (WST) stock fell by 0.82% after Janus Henderson Group PLC reduced its stake, reflecting a broader trend of adjustments by institutional investors amid mixed analyst ratings and updated target prices for the stock.

West Pharmaceutical Services (WST) stock fell by 0.82% despite a forecasted increase in earnings estimates by Zacks Research, likely due to overall market trends or adjustments in investor sentiment following mixed analyst ratings and recent quarterly performance that showed a year-over-year earnings decline.

West Pharmaceutical Services (WST) stock rose 0.27% amidst ongoing investor concerns and class action litigation related to disappointing revenue forecasts and operational challenges reported earlier in 2025, likely reflecting a slight market correction or response to speculative trading as the upcoming class action deadline approaches.

West Pharmaceutical Services (WST) stock increased by 2.83% following the Gates Foundation's recent investment of £74.82 million ($99.51 million) in the company, despite existing challenges it faces, including a class action lawsuit and disappointing revenue forecasts.

West Pharmaceutical Services (WST) stock rose 2.83% after ongoing investigations into allegations of securities fraud against its officers and directors regarding misleading statements about the company's financial health and the operational performance of its products, which has raised investor interest.

The article discusses the initiation of class action lawsuits on behalf of investors against West Pharmaceutical Services, among other companies, with specific issues related to misleading statements impacting stock performance, while WST stock rose 1.93% likely due to general market conditions or investor sentiment rather than the ongoing legal issues.

The article discusses the initiation of class action lawsuits on behalf of investors against West Ph

West Pharmaceutical Services (WST) saw its stock decline by 4.25% due to a combination of policy uncertainties, weakened earnings outlooks, and challenges in their high-value product segment, exacerbated by facility constraints and lower-than-expected pricing despite strong overall demand.

West Pharmaceutical Services (WST) saw its stock decline by 4

West Pharmaceutical Services (WST) stock declined by 4.25% due to the announcement of a class action lawsuit alleging securities violations and revealing disappointing revenue forecasts driven by operational inefficiencies and loss of major customers.

West Pharmaceutical Services (WST) stock declined by 4

West Pharmaceutical Services (WST) stock declined by 1.64% due to ongoing class action allegations that the company misled investors about its business prospects, particularly regarding significant destocking in its high-margin products and operational inefficiencies that affected profit margins.

West Pharmaceutical Services (WST) stock declined by 0.78% amid a class action lawsuit alleging misleading statements regarding the company's financial performance and significant operational challenges, including customer losses and margin pressures linked to their SmartDose product.

West Pharmaceutical Services (WST) stock was down 0.78% due to the filing of a class action lawsuit alleging securities fraud and the company's previously issued weak revenue and earnings forecasts, which were influenced by losing major customers and concerns about the profitability of its SmartDose wearable injector devices.

West Pharmaceutical Services (WST) stock was down 0

West Pharmaceutical Services (WST) stock rose by 0.75% amidst a class action lawsuit alleging misleading statements regarding its financial health and product margins, but the increase may reflect investor optimism or market responses unrelated to the negative allegations.

West Pharmaceutical Services (WST) stock rose by 3.79% following the filing of a securities class-action lawsuit related to alleged misrepresentations about the company's performance and future prospects, which may have prompted investor reactions to the ongoing developments. 

The stock increase may be attributed to investor speculation or recovery efforts in response to the previous sharp decline after the company's weak earnings forecast, which highlighted the company's struggles with margin pressures and contract losses.

West Pharmaceutical Services (WST) stock rose by 3

West Pharmaceutical Services (WST) stock increased by 3.79% following an investigation into allegations of fiduciary breaches by its officers and directors related to misleading financial statements and operational inefficiencies that were previously disclosed to shareholders, which likely prompted investor confidence and optimism regarding potential corporate reforms.

West Pharmaceutical Services (WST) stock increased by 3

West Pharmaceutical Services (WST) stock fell by -2.66% primarily due to market shifts favoring lower-volatility equities and concerns about investor expectations not being met, similar to challenges faced by other companies like Marvell Technology Inc., which were highlighted in Artisan Partners' Q1 2025 investor letter.

West Pharmaceutical Services (WST) stock fell by -2

West Pharmaceutical Services (NYSE: WST) saw a 0.49% increase in stock price, with investors responding positively despite recent challenges highlighted in an investment letter that noted its earnings exceeded estimates but were tempered by disappointing forward guidance and margin pressures.

West Pharmaceutical Services (NYSE: WST) saw a 0

West Pharmaceutical Services (WST) stock fell by -1.23% due to market dynamics affecting investor sentiment towards its collaboration with small-cap pharmaceutical companies like scPharmaceuticals and Purple Biotech, which are both competing in the medical field.

West Pharmaceutical Services (WST) stock fell by -1

West Pharmaceutical Services (WST) stock fell by 1.23% following a downgrade in Q3 2025 earnings per share estimates from William Blair, indicating decreased earnings expectations for the medical instruments supplier.

Headline	Summary	Source
West Pharmaceutical Services (NYSE: WST) stock fell by 1	West Pharmaceutical Services (NYSE: WST) stock fell by 1.87% despite a positive earnings report and upgraded earnings estimates, likely due to market reaction to overall economic conditions or investor sentiment despite better-than-expected results.	ETF Daily News
West Pharmaceutical Services (WST) shares experienced a 1	West Pharmaceutical Services (WST) shares experienced a 1.87% decline, despite a consensus rating of "Moderate Buy" from analysts and a record of positive quarterly earnings, likely due to market fluctuations or profit-taking following the stock's previous performance.	ETF Daily News

WST

Latest News & Analysis